AptarGroup, Inc.'s SEC filings document operating results, governance matters and capital-structure activity for a NYSE-listed maker of drug delivery and consumer-product dispensing technologies. Form 8-K reports furnish quarterly and annual results, segment commentary for Pharma, Beauty and Closures, shareholder returns and material events tied to the company's operations.
The filing record also includes proxy materials and annual meeting vote results covering director elections, advisory compensation matters and stockholder voting items. Capital disclosures include common stock registered under the Exchange Act, shelf-registration activity and completed debt financing, including the 4.750% Senior Notes due 2031 issued under an indenture.
APTARGROUP, INC. Segment President Marc Prieur reported receiving a grant of 7,969 shares of Common Stock as a compensation-related award coded as a “Grant, award, or other acquisition.” The shares were acquired at $0.00 per share, bringing his direct holdings to 24,323 shares of AptarGroup common stock.
APTARGROUP, INC. Segment President and CEO Designate Gael Touya reported routine equity compensation activity in Common Stock. He received a grant of 7,454 shares at no cost and had 4,175 shares withheld to cover taxes, valued at about $127.21 per share.
After these non-market transactions, Touya directly holds 32,842 shares of AptarGroup common stock. The filing reflects compensation-related share movements and tax withholding rather than open-market buying or selling.
APTARGROUP, INC. executive Xiangwei Gong, President, Asia, reported routine equity compensation changes. Gong received a grant of 6,502 shares of Common Stock, increasing his direct holdings, and had 2,559 shares withheld at $119.02 per share to cover tax obligations.
After these transactions, Gong directly holds 14,974 shares of Common Stock and indirectly holds 642 shares through a 401(k) trust. The filing reflects compensation-related activity rather than open-market buying or selling.
AptarGroup, Inc. Chief Accounting Officer Daniel Ackerman received an award of 2,410 shares of common stock on May 1, 2026. The shares were acquired at a stated price of $0.00 per share, indicating a grant rather than a market purchase. Following this award, Ackerman directly holds a total of 32,779 shares of AptarGroup common stock.
AptarGroup executive Irene Elizabeth Hudson, EVP and Chief Legal Officer, reported routine equity compensation activity in the company’s Common Stock. She received a grant of 684 shares as a compensation award. To cover tax obligations, 247 shares were disposed of through a tax-withholding transaction at $119.02 per share, which is not an open-market sale. After these transactions, she directly holds 1,902 shares of AptarGroup common stock.
AptarGroup, Inc. President and CEO Stephan B. Tanda reported compensation-related stock activity. On May 1, 2026, he received a grant of 39,485 shares of common stock at $0.00 per share, increasing his direct holdings to 254,267 shares. On the same date, 15,538 shares were disposed of at $119.02 per share as a tax-withholding transaction, meaning shares were withheld to cover tax obligations rather than sold in an open-market trade. He also reports 3,138 shares held indirectly through a 401(k) trust.
APTARGROUP, INC. Chief Human Resources Officer Shiela Vinczeller reported routine equity compensation activity. She received a grant of 6,032 shares of common stock as a stock award. On the same date, 2,150 shares were disposed of as a tax-withholding disposition at $119.02 per share, covering tax obligations rather than representing an open-market sale. After these transactions, she directly owned 30,633 shares of AptarGroup common stock.
AptarGroup, Inc. reported first-quarter 2026 net sales of $982.9 million, up 11% from $887.3 million a year earlier. Foreign exchange and acquisitions drove most of the increase, leaving core sales roughly flat. Net income attributable to AptarGroup was $72.7 million, down from $78.8 million, and diluted EPS declined to $1.12 from $1.17 as margins compressed.
Pharma sales rose to $438.6 million but core sales dipped 1% on lower emergency medicine volumes, while Beauty and Closures delivered modest core growth. Operating margin decreased to 10.9% from 12.8%. Cash flow from operations strengthened to $118.7 million, supporting $65.4 million of capital spending and $100.0 million of share repurchases under a new $600 million authorization.
AptarGroup reported mixed first quarter 2026 results, with solid top-line growth but softer profit metrics. Net sales rose 11% to $982.9 million, while reported net income declined 8% to $72.8 million and diluted earnings per share slipped to $1.12 from $1.17.
On an adjusted basis, earnings per share were $1.19, down from $1.30 a year earlier at comparable exchange rates, and adjusted EBITDA margin narrowed to 19.2% from 20.7% as mix and operational issues weighed on profitability. Pharma and Closures saw core sales pressure from emergency medicine destocking, lower resin pricing and temporary plant disruptions, while Beauty delivered 3% core growth.
The company returned $131 million to shareholders through dividends and share repurchases in the quarter, including buying back 707,000 shares for $100 million, and the board approved a quarterly dividend of $0.48 per share. For the second quarter of 2026, AptarGroup expects adjusted earnings per share between $1.32 and $1.40, assuming an effective tax rate of 22.5% to 24.5% and a 1.18 EUR/USD exchange rate. The company also announced that Gael Touya will become CEO effective September 1, 2026.
AptarGroup Inc reports an institutional beneficial ownership filing showing Vanguard Capital Management beneficially owns 3,376,965 shares of Common Stock, representing 5.29% of the class. The filing states Vanguard has sole dispositive power over 3,376,965 shares and sole voting power over 491,668 shares. The disclosure explains these holdings reflect securities managed across Vanguard affiliates and funds.